Microarray‑based analysis of COL11A1 and TWIST1 as important differentially‑expressed pathogenic genes between left and right‑sided colon cancer

Su,Chen; Zhao,Jiabao; Hong,Xinya; Yang,Sijiu; Jiang,Ying; Hou,Jingjing

doi:10.3892/mmr.2019.10667

Microarray‑based analysis of COL11A1 and TWIST1 as important differentially‑expressed pathogenic genes between left and right‑sided colon cancer

Authors:
- Chen Su
- Jiabao Zhao
- Xinya Hong
- Sijiu Yang
- Ying Jiang
- Jingjing Hou
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Medical Imaging and Ultrasound, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Critical Care Medicine, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Clinical Medicine, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: September 10, 2019 https://doi.org/10.3892/mmr.2019.10667
Pages: 4202-4214
Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colonic cancer has become a main reason of mortality associated with cancer; however, left and right‑sided colonic cancer have diverse outcomes in terms of epidemiological, histological, clinical parameters and prognosis. We aimed to examine the discrepancies between these two types of colon cancers to identify potential therapeutic targets. In the present study, three gene expression profiles (GSE44076, GSE31595, GSE26906) from Gene Expression Omnibus (GEO) database were downloaded and further analyzed. A PPI (protein‑protein interaction) network of the differentially‑expressed genes (DEGs) of GSE44076 between tumor and normal was established with the Search Tool for the Retrieval of Interacting Genes database. Then, the DEGs of these two colon cancers (left, right) samples were identified. Subsequently, the intersection of DEGs of left and right‑sided colon cancer samples obtained from three databases, and DEGs of tumor and normal samples were analyzed. Collagen type XI α1 chain (COL11A1), Twist family bHLH transcription factor 1 (TWIST1), insulin‑like 5 and chromogranin A were upregulated proteins, while 3β‑hydroxysteroid dehydrogenase was downregulated protein in right colon cancer than in left‑sided tumor samples. Through further experimental verification, we revealed that COL11A1 and TWIST1 were significantly upregulated at the mRNA and protein levels within right‑sided colon cancer compared with in left‑sided colon cancer samples (P<0.05), consistent with bioinformatical analysis. Furthermore, a positive correlation between COL11A1 and TWIST1 protein expression was observed (P<0.0276). Collectively, our data showed that COL11A1 and TWIST1 may be potential prognostic indicators and molecular targets for the treatment of right‑sided colon cancer.

View Figures

View References

1	Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F and Arnold M: Global trends in colorectal cancer mortality: Projections to the year 2035. Int J Cancer. 144:2992–3000. 2019. View Article : Google Scholar : PubMed/NCBI
2	Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I and Lippert H; Colon/Rectum Carcinomas (Primary Tumor) Study Group, : Comparison of 17,641 patients with right- and left-sided colon cancer: Differences in epidemiology perioperative course, histology, and survival. Dis Colon Rectum. 53:57–64. 2010. View Article : Google Scholar : PubMed/NCBI
3	Alexiusdottir KK, Möller PH, Snaebjornsson P, Jonasson L, Olafsdottir EJ, Björnsson ES, Tryggvadottir L and Jonasson JG: Association of symptoms of colon cancer patients with tumor location and TNM tumor stage. Scand J Gastroenterol. 47:795–801. 2012. View Article : Google Scholar : PubMed/NCBI
4	Hansen IO and Jess P: Possible better long-term survival in left versus right-sided colon cancer-a systematic review. Dan Med J. 59:A44442012.PubMed/NCBI
5	Solé X, Crous-Bou M, Cordero D, Olivares D, Guinó E, Sanz-Pamplona R, Rodriguez-Moranta F, Sanjuan X, de Oca J, Salazar R and Moreno V: Discovery and validation of new potential biomarkers for early detection of colon cancer. PLoS One. 9:e1067482014. View Article : Google Scholar : PubMed/NCBI
6	Thorsteinsson M, Kirkeby LT, Hansen R, Lund LR, Sørensen LT, Gerds TA, Jess P and Olsen J: Gene expression profiles in stages II and III colon cancers: Application of a 128-gene signature. Int J Colorectal Dis. 27:1579–1586. 2012. View Article : Google Scholar : PubMed/NCBI
7	Birnbaum DJ, Laibe S, Ferrari A, Lagarde A, Fabre AJ, Monges G, Birnbaum D and Olschwang S; COL2 Project, : Expression profiles in stage II colon cancer according to APC gene status 1 2. Transl Oncol. 5:72–76. 2012. View Article : Google Scholar : PubMed/NCBI
8	Fischer H, Stenling R, Rubio C and Lindblom A: Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 22:875–878. 2001. View Article : Google Scholar : PubMed/NCBI
9	Fischer H, Salahshor S, Stenling R, Björk J, Lindmark G, Iselius L, Rubio C and Lindblom A: COL11A1 in FAP polyps and in sporadic colorectal tumors. Bmc Cancer. 1:172001. View Article : Google Scholar : PubMed/NCBI
10	Bowen KB, Reimers AP, Luman S, Kronz JD, Fyffe WE and Oxford JT: Immunohistochemical localization of collagen type XI alpha1 and alpha2 chains in human colon tissue. J Histochem Cytochem. 56:275–283. 2008. View Article : Google Scholar : PubMed/NCBI
11	Badea L, Herlea V, Dima SO, Dumitrascu T and Popescu I: Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 55:2016–2027. 2008.PubMed/NCBI
12	Chong IW, Chang MY, Chang HC, Yu YP, Sheu CC, Tsai JR, Hung JY, Chou SH, Tsai MS, Hwang JJ and Lin SR: Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep. 16:981–988. 2006.PubMed/NCBI
13	Feng Y, Sun B, Li X, Zhang L, Niu Y, Xiao C, Ning L, Fang Z, Wang Y, Zhang L, et al: Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat. 103:319–329. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wu YH, Chang TH, Huang YF, Huang HD and Chou CY: COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene. 33:3432–3440. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis JR and Thomas SM: Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion. Br J Cancer. 109:3049–3056. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wu YH, Chang TH, Huang YF, Chen CC and Chou CY: COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget. 6:23748–23763. 2015.PubMed/NCBI
17	Galván JA, García-Martínez J, Vázquez-Villa F, García-Ocaña M, García-Pravia C, Menéndez-Rodríguez P, González-del Rey C, Barneo-Serra L and de los Toyos JR: Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma. BMC Cancer. 14:8672014. View Article : Google Scholar : PubMed/NCBI
18	Brabletz T: EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012. View Article : Google Scholar : PubMed/NCBI
19	Eide T, Ramberg H, Glackin C, Tindall D and Taskén KA: TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells. Cancer Cell Int. 13:42013. View Article : Google Scholar : PubMed/NCBI
20	Qin Q, Xu Y, He T, Qin C and Xu J: Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar : PubMed/NCBI
21	Salerno P, Garcia-Rostan G, Piccinin S, Bencivenga TC, Di Maro G, Doglioni C, Basolo F, Maestro R, Fusco A, Santoro M and Salvatore G: TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. J Clin Endocrinol Metab. 96:E772–E781. 2011. View Article : Google Scholar : PubMed/NCBI
22	Lee KW, Kim JH, Han S, Sung CO, Do IG, Ko YH, Um SH and Kim SH: Twist1 Is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann Surg Oncol. 19:326–335. 2012. View Article : Google Scholar : PubMed/NCBI
23	Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD and Wang LH: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
24	Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS and Wu KJ: Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 64:1082–1089. 2009. View Article : Google Scholar : PubMed/NCBI
25	Yan-Qi Z, Xue-Yan G, Shuang H, Yu C, Fu-Lin G, Fei-Hu B, Shi-Ren S, Xu Feng W, Jie D and Dai-Ming F: Expression and significance of TWIST basic helix-loop-helix protein over-expression in gastric cancer. Pathology. 39:470–475. 2007. View Article : Google Scholar : PubMed/NCBI
26	Satoh K, Hamada S, Kimura K, Kanno A, Hirota M, Umino J, Fujibuchi W, Masamune A, Tanaka N, Miura K, et al: Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol. 172:926–939. 2008. View Article : Google Scholar : PubMed/NCBI
27	Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, et al: Twist expression promotes migration and invasion in hepatocellular carcinoma. Bmc Cancer. 9:2402009. View Article : Google Scholar : PubMed/NCBI
28	Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, et al: TWIST1 polymorphisms predict survival in patients with metastatic colorectal cancer receiving first-line bevacizumab plus oxaliplatin-based chemotherapy. Mol Cancer Ther. 15:1405–1411. 2016. View Article : Google Scholar : PubMed/NCBI
29	Missaoui N, Hmissa S, Trabelsi A, Traoré C, Mokni M, Dante R and Frappart L: Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathol Res Pract. 207:37–42. 2011. View Article : Google Scholar : PubMed/NCBI
30	Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, et al: Twist1 suppresses senescence programs and thereby accelerates and maintains mutant kras-induced lung tumorigenesis. PLoS Genet. 8:e10026502012. View Article : Google Scholar : PubMed/NCBI
31	Ruppenthal RD, Nicolini C, Filho AF, Meurer R, Damin AP, Rohe A, Alexandre CO and Damin DC: TWIST1 promoter methylation in primary colorectal carcinoma. Pathol Oncol Res. 17:867–872. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhao N, Sun BC, Zhao XL, Liu ZY, Sun T, Qiu ZQ, Gu Q, Che N and Dong XY: Coexpression of Bcl-2 with epithelial-mesenchymal transition regulators is a prognostic indicator in hepatocellular carcinoma. Med Oncol. 29:2780–2792. 2012. View Article : Google Scholar : PubMed/NCBI
33	World Medical Association Inc, . Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 107:403–405. 2009.PubMed/NCBI
34	Council for International Organizations of Medical Sciences, . International ethical guidelines for biomedical research involving human subjects. Bull Med Ethics. 10:17–23. 2002.
35	Bankowski Z: Council for International Organizations of Medical Sciences. J Med Imag Radiation Oncol. 15:83–87. 1971.
36	Gautier L, Cope L, Bolstad BM and Irizarry RA: Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
37	Smyth GK: LIMMA: Linear models for microarray dataBioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry R and Huber W: Statistics for Biology and Health. Springer; New York, NY: pp. 397–420. 2005, View Article : Google Scholar
38	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
39	Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C and Jensen LJ: STRING v9. 1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41:D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI
40	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
41	Mizuno H, Kitada K, Nakai K and Sarai A: PrognoScan: A new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
42	Weiss HL, Niwas S, Grizzle WE and Piyathilake C: Receiver operating characteristic (ROC) to determine cut-off points of biomarkers in lung cancer patients. Dis Markers. 19:273–278. 2003. View Article : Google Scholar : PubMed/NCBI
43	Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4:P32003. View Article : Google Scholar : PubMed/NCBI
44	Wu YH, Huang YF, Chang TH and Chou CY: Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression. Int J Cancer. 141:2305–2317. 2017. View Article : Google Scholar : PubMed/NCBI
45	Bufill JA: Colorectal cancer: Evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 113:779–788. 1990. View Article : Google Scholar : PubMed/NCBI
46	Nitsche U, Stögbauer F, Späth C, Haller B, Wilhelm D, Friess H and Bader FG: Right sided colon cancer as a distinct histopathological subtype with reduced prognosis. Dig Surg. 33:157–163. 2016. View Article : Google Scholar : PubMed/NCBI
47	Venook AP, Ou FS, Lenz HJ, Kabbarah O, QU X and Niedzwiecki D: Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 35:3503. 2017. View Article : Google Scholar
48	von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, et al: Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: An analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 140:1607–1614. 2014. View Article : Google Scholar : PubMed/NCBI
49	Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, et al: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 51:1405–1414. 2015. View Article : Google Scholar : PubMed/NCBI
50	Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, Zhu LZ, Fang XF and Yuan Y: Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 21:6470–6478. 2015. View Article : Google Scholar : PubMed/NCBI
51	Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N and Allegra CJ; National Cancer Institute, : Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol. 25:767–772. 2007. View Article : Google Scholar : PubMed/NCBI
52	Minoo P, Zlobec I, Peterson M, Terracciano L and Lugli A: Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 37:707–718. 2010. View Article : Google Scholar : PubMed/NCBI
53	Deng G, Kakar S, Tanaka H, Matsuzaki K, Miura S, Sleisenger MH and Kim YS: Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur J Cancer. 44:1290–1301. 2008. View Article : Google Scholar : PubMed/NCBI
54	Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, et al: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 61:847–854. 2012. View Article : Google Scholar : PubMed/NCBI
55	Phipps AI, Lindor NM, Jenkins MA, Baron JA, Win AK, Gallinger S, Gryfe R and Newcomb PA: Colon and rectal cancer survival by tumor location and microsatellite instability: The Colon Cancer Family Registry. DisColon Rectum. 56:937–944. 2013. View Article : Google Scholar
56	Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, et al: Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 24:1062–1072. 2018. View Article : Google Scholar : PubMed/NCBI
57	Liu F, Li C, Jia H, Yang L, Wu Y, Zhao J, Cai S, Zhu J and Xu Y: Is there a prognostic value of tumor location among Chinese patients with colorectal cancer? Oncotarget. 8:38682–38692. 2017.PubMed/NCBI
58	Slattery ML, Curtin K, Wolff RK, Boucher KM, Sweeney C, Edwards S, Caan BJ and Samowitz W: A comparison of colon and rectal somatic DNA alterations. DisColon Rectum. 52:1304–1311. 2009. View Article : Google Scholar
59	Liotta LA, Rao CN and Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest. 49:636–649. 1983.PubMed/NCBI
60	Mio F, Chiba K, Hirose Y, Kawaguchi Y, Mikami Y, Oya T, Mori M, Kamata M, Matsumoto M, Ozaki K, et al: A Functional Polymorphism in COL11A1, which encodes the alpha 1 chain of type XI collagen, is Associated with Susceptibility to Lumbar Disc Herniation. Am J Hum Genet. 81:1271–1277. 2007. View Article : Google Scholar : PubMed/NCBI
61	Barkan D, Green JE and Chambers AF: Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer. 46:1181–1188. 2010. View Article : Google Scholar : PubMed/NCBI
62	Hynes RO: The Extracellular Matrix: Not Just Pretty Fibrils. Science. 326:1216–1219. 2009. View Article : Google Scholar : PubMed/NCBI
63	Raglow Z and Thomas SM: Tumor matrix protein collagen XIα1 in cancer. Cancer Lett. 357:448–453. 2015. View Article : Google Scholar : PubMed/NCBI
64	Egeblad M, Rasch MG and Weaver VM: Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 22:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
65	Prockop DJ, Kivirikko KI, Tuderman L and Guzman NA: The biosynthesis of collagen and its disorders (second of two parts). N Engl J Med. 301:77–85. 1979. View Article : Google Scholar : PubMed/NCBI
66	Li Y, Lacerda DA, Warman ML, Beier DR, Yoshioka H, Ninomiya Y, Oxford JT, Morris NP, Andrikopoulos K, Ramirez F, et al: A fibrillar collagen gene, Col11a1, is essential for skeletal morphogenesis. Cell. 80:423–430. 1995. View Article : Google Scholar : PubMed/NCBI
67	Donoso LA, Edwards AO, Frost AT, Ritter R III, Ahmad N, Vrabec T, Rogers J, Meyer D and Parma S: Clinical variability of Stickler syndrome: role of exon 2 of the collagen COL2A1 gene. Surv Ophthalmol. 48:191–203. 2003. View Article : Google Scholar : PubMed/NCBI
68	Annunen S, Körkkö J, Czarny M, Warman ML, Brunner HG, Kääriäinen H, Mulliken JB, Tranebjaerg L, Brooks DG, Cox GF, et al: Splicing mutations of 54-bp exons in the COL11A1 gene cause marshall syndrome, but other mutations cause overlapping marshall/stickler phenotypes. Am J Hum Genet. 65:974–983. 1999. View Article : Google Scholar : PubMed/NCBI
69	Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ and Wang XF: Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 22:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
70	Prieto-García E, Díaz-García CV, García-Ruiz I and Agulló-Ortuño MT: Epithelial-to-mesenchymal transition in tumor progression. Med Oncol. 34:1222017. View Article : Google Scholar : PubMed/NCBI
71	Kim A, Bae YK, Gu MJ, Kim JY, Jang KY, Bae HI, Lee HJ and Hong SM: Epithelial-mesenchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma. Pathology. 45:567–573. 2013. View Article : Google Scholar : PubMed/NCBI
72	Kudo-Saito C, Shirako H, Takeuchi T and Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
73	Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S and Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. Embo Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
74	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
75	Wahl GM: BS1-1: Stem cells, cancer, and cancer stem cells. Cancer Res. 71:BS12011.
76	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
77	Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
78	Zhu DJ, Chen XW, Zhang WJ, Wang JZ, Ouyang MZ, Zhong Q and Liu CC: Twist1 is a potential prognostic marker for colorectal cancer and associated with chemoresistance. Am J Cancer Res. 5:2000–2011. 2015.PubMed/NCBI
79	Puisieux A, Valsesia-Wittmann S and Ansieau S: A twist for survival and cancer progression. Br J Cancer. 94:13–17. 2006. View Article : Google Scholar : PubMed/NCBI
80	Firulli AB and Conway SJ: Phosphoregulation of Twist1 provides a mechanism of cell fate control. Curr Med Chem. 15:2641–2647. 2008. View Article : Google Scholar : PubMed/NCBI
81	Fu J, Qin L, He T, Qin J, Hong J, Wong J, Liao L and Xu J: The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 21:275–289. 2011. View Article : Google Scholar : PubMed/NCBI
82	Qin L, Liu Z, Chen H and Xu J: The steroid receptor coactivator-1 (SRC-1) regulates twist expression and promotes breast cancer metastasis. Cancer Res. 69:3819–3827. 2009. View Article : Google Scholar : PubMed/NCBI
83	Vernon AE and LaBonne C: Tumor metastasis: A new twist on epithelial-mesenchymal transitions. Curr Biol. 14:R719–R721. 2004. View Article : Google Scholar : PubMed/NCBI
84	Karreth F and Tuveson DA: Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 3:1058–1059. 2004. View Article : Google Scholar : PubMed/NCBI
85	Yang J, Mani SA and Weinberg RA: Exploring a new twist on tumor metastasis. Cancer Res. 66:4549–4552. 2006. View Article : Google Scholar : PubMed/NCBI
86	Venook A, Niedzwiecki D, Lenz HJ, et al: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 32:S182014. View Article : Google Scholar